A1C target achievement rates — sema vs tirz comparison

TrialTracker_MD said:

HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 21%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

A narrower follow-up, since the general answer is now clear:

How would you tell the difference between that and the alternative explanation?

anders_CPH said:

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 21%.

My labs after 6 months on glycaemic control: A1C 6.2%, fasting glucose 92 mg/dL, fasting insulin 7 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.9% and fasting glucose was 137 mg/dL. The improvement has been dramatic and consistent.

anders_CPH said:

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 21%.

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 11 months: periods became regular for the first time in a decade, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my fertility specialist is optimistic about future conception.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

Dr.NutriCornell said:

My labs after 6 months on glycaemic control: A1C 6.2%, fasting glucose 92 mg/dL, fasting insulin 7 uIU/mL.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.